Historically, and probably the mainstream hypothesis, is that you need chemo to be systemic in order to take care of micrometastatic disease (tumors that you cannot see). However, with the advent of immunooncology (IO) therapies (drugs that help your body recognize the tumor) and the benefits of having chemo + IO drugs is challenging that dogma. Certain chemo drugs are known to trigger an immune response. Having a technology that gives intense amount of chemo at the tumor and without diminishing the persons immune system. Our technology opens the door to have this effect in humans. We have seen those effects in mice studies and presented the results in cancer conferences.